Lupin Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is VALSARTAN USP, with a corresponding US DMF Number 19301.
Remarkably, this DMF maintains an Active status since its submission on March 27, 2006, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of February 24, 2019, and payment made on February 15, 2019, indicating their dedication to facilitating drug approvals, Categorized as Type II